Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Endologix begins trial geared towards US cuff approval:

This article was originally published in Clinica

Executive Summary

Endologix, of Irvine, California, has started a multicentre, controlled investigational device exemption (IDE) trial intended to support US FDA approval of the large 34mm diameter Powerlink infrarenal cuff in conjunction with the firm's Powerlink product. Powerlink is a bifurcated endoluminal stent graft (ELG) approved by the FDA for the minimally-invasive treatment of abdominal aortic aneurysm (AAA). It is estimated that 35,000 ELG procedures will be performed in the US this year.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT049497

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel